AXON Axovant Sciences Ltd.

1.01
-0.12  -11%
Previous Close 1.13
Open 0.95
Price To Book 6.31
Market Cap 123502141
Shares 122,279,348
Volume 4,331,755
Short Ratio
Av. Daily Volume 662,671

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181233854
  2. 8-K - Current report 181233826
  3. CT ORDER - Confidential treatment order 181209004
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167022
  5. 8-K - Current report 181166363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released January 2018 - negative data.
Intepirdine
Gait and Balance Impairments in Dementia
Phase 2 data released December 10, 2018. Primary endpoint not met.
Nelotanserin
DLB patients experiencing REM Behavior Disorder (RBD)
Phase 2b data released January 8, 2018 - negative data.
Intepirdine - HEADWAY-DLB
Dementia with Lewy bodies (DLB)
Phase 2 data released January 8, 2018. Dementia endpoint missed.
Nelotanserin
Visual hallucinations in subjects with Lewy body dementia
Phase 3 data released September 26, 2017 - primary endpoints not met.
Intepirdine - MINDSET
Alzheimer's disease
Phase 1/2 data from first two patients due March 2019.
AXO-Lenti-PD - SUNRISE-PD
Parkinson's disease

Latest News

  1. Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares
  2. Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences
  3. Axovant Sciences Announces Public Offering of Common Shares
  4. Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School
  5. See what the IHS Markit Score report has to say about Axovant Sciences Ltd.
  6. Here's Why Axovant Sciences Lost as Much as 29.2% Today
  7. A Tale Of 2 Biotechs: Axsome, Axovant Report Contrasting Outcomes For Neurologic Drugs
  8. Market Morning: Brexit Balk, Inflation Data, Tesla Swoops In On GM
  9. UPDATE: Axovant shares slide 30% premarket after trial of treatment for sleep disorder fails to meet main goal
  10. Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
  11. Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinson’s Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial
  12. Here's how Moderna's IPO stacks up against others in biotech
  13. FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101
  14. Goodwin wins lucrative work on Moderna's massive IPO
  15. Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center
  16. Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline
  17. Novartis Gets Approval for Gene Therapy Luxturna in Europe
  18. Axovant: Fiscal 2Q Earnings Snapshot
  19. Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 181233854
  2. 8-K - Current report 181233826
  3. CT ORDER - Confidential treatment order 181209004
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167022
  5. 8-K - Current report 181166363
  6. 8-K - Current report 181101443
  7. CT ORDER - Confidential treatment order 181039914
  8. 8-K - Current report 181026065
  9. S-8 - Securities to be offered to employees in employee benefit plans 181024047
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998959